| Indication1 |
 |
|
| Reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma, chronic angle-closure glaucoma and ocular hypertension. |
| |
| Clinical Evidence |
|
|
- Comparable to bimatoprost and travoprost in their ability to reduce IOP in open-angle glaucoma and ocular hypertension2
- Latanoprost exhibited greater ocular tolerability2
Figure 1. Unadjusted 8:00 AM mean IOP levels by treatment and visit (intent-to-treat population)
Figure 2. Mean hyperemia (investigators’ assessments) score by treatment and visit |
| |
| Safety Profile1 |
|
|
| CI: |
Known hypersensitivity to any component of Xalatan. |
| |
|
| SP: |
Inflammatory, neovascular, angle-closure or congenital glaucoma, pigmentary glaucoma, pregnancy and lactation, contact lens users. Limited experience in open-angle glaucoma of pseudophakic patients. No experience in acute attacks of closed-angle glaucoma. |
| |
|
| AR: |
Increased pigmentation of the iris. |
| |
|
| DI: |
Effects additive to β-adrenergic antagonists, adrenergic agonists, carbonic anhydrase inhibitors and cholinergic agonists. |
|
| Dosages1 |
|
|
| Adults, including elderly One drop (1.5 mcg) in the affected eye or eyes once daily in the evening. If one dose is missed, treatment should continue with the next dose as normal. |
| Strengths1 |
|
|
| 0.005% (50 mcg/mL). |
| Packing1 |
|
|
| Eye drops 2.5 mL solution in a 5 mL bottle. |
| References |
|
|
1. MIMS Annual Hong Kong. 2007/2008 edition.
2. Parrish RK, et al. Am J Ophthalmol 2003;135:688-703. |
Please review the full product information or package insert before prescribing.
